Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients-Reference-Cited by-同舟云学术

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Published:2018-02-19 Issue:3 Volume:46 Page:431-434
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Hakki Morgan^ORCID,Lewis James S.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s15010-018-1125-5/fulltext.html

Reference20 articles.

1. Satlin MJ, Walsh TJ. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017. https://doi.org/10.1111/tid.12762 .

2. Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012;91:1299–304. https://doi.org/10.1007/s00277-012-1424-3 .

3. Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1–3. https://doi.org/10.3324/haematol.2010.036640 author reply e4.

4. Trecarichi EM, Tumbarello M. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27:200–10. https://doi.org/10.1097/QCO.0000000000000038 .

5. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother. 2017;72:1386–95. https://doi.org/10.1093/jac/dkx009 .

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings—A French Real-world Study;Open Forum Infectious Diseases;2024-02-01

2. Important Considerations in the Intensive Care Management of Acute Leukemias;Journal of Intensive Care Medicine;2023-11-21

3. Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR);Annals of Clinical Microbiology and Antimicrobials;2022-10-03

4. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study;Journal of Infection and Public Health;2022-10

5. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study);Microbiology Spectrum;2022-06-29